{"ticker": {"uuid": "47b52f9c-94a6-4983-aea8-889ad5b6917d", "symbol": "688428", "name": "InnoCare Pharma Limited", "exchange": "SHH", "country": "CN", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "InnoCare Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE9NdVBtOFJlNkN3UWE0OWtFdjlVWGl6TW9fRHROZGRvVVlFWXVmSzc2ZS1uejZ5ZFJFOFN4NWpVd2N3cXltTkZJb1MtdEs4bXdLaWQ4QklUWHB3a1poTmdkTHhvLUFYaHFFTG5qNGJB?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-07-20T19:38:49+00:00", "published_display": "20 Jul 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-14T10:21:47+00:00", "published_display": "14 Jul 2026 10:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is InnoCare Pharma (SEHK:9969) Undervalued On Its Breakthrough Lupus Trial Results?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T22:20:48+00:00", "published_display": "10 Jul 2026 22:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOTFZOcGNETTBDSVRLS3BwS0NiandvMVluTjd6eW91S1g2MW1OMW5pWXZCYUt2TldxeFlUaEFJaGpBZjY2YjRCd0dQQm4yTUNjOXI0M3dDSU1ZNEVHQzhUYWxmOXlEWWE0TlVnSVJzNGprbHlDR1lkanZVckNJbEtkNkVhT3lyaGJ6WWxjMWkwa2VYN3N3eTJhMDRwemZmMU1KZ3RTWnpLdjlVeEtIdGNEVkJWRlZ2aENwNjhEX29DaFl5RkFYNkpCWA?oc=5", "source_name": "Sahm", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InnoCare Pharma posts 134% revenue surge in 2025, recording annual profit for first time", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBiTWtVUlBZeHRyNE9Kc0dSVEJFWjBweFo3X2ZLZHB4V19JMk5tcUhISWhzbWVPdDJrenNnWGhqdm5jZUxhZlVjdGQxem12M3kyZ0syTml5anVwR0R2bkFUSi1EczVVMDJvNUNfdDVGakFRcnJjQUF4WFNIS0pBQQ?oc=5", "source_name": "China Daily", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas makes big bet on MS drug, striking $2B licensing deal with InnoCare", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOU1VfUnJXTE5fTUNGa1VoMk1oQzlWT28zRzdVUTkzaVJDYS1qbjh6VGlGSDZVRUdBWHRQakRqbUYxNmtCdTZ5N1VJOG5scVhnVWFRUThlS01yV3UxT3hZaHhwLUFIb1RaeTUyX0NuUXJPSURmS09OeGY1ck8tUF84T1JnS2NRMnoyYkFzbVNacGo3QzUtUHUweUEwVDR3Rm04?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcHRlT1lSSWxFZVFQWFhFRlFqcnFteFBiSnJjc3ZLMl9XUWRFcERwNVZheDNFZnJUTzNGWnVnSlJmYVJaUWpNTi1OX2EtTElkT2ZVYzhDSEJpRmVFdmMySmlaU1lrZ296V1RqUVhYZlpxWW5SUUtaT0pubENwbUZVV2JtYWY0aEhnUGpSMmE5UXh6Sl9FY3BDQy1jVUJyeWJzYW40akdRMVJCOGxuRHM3QUE0N0ZrVHUyMlhuOTNfdUhzQmVURUR6d2JuVTluemxpRkxaSmxudjFjdw?oc=5", "source_name": "Reuters", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPeHlXLWxLOU8wS1hRTUNtU3lFR0x6c3RXWXZpYVItWHNGd1FqLW92MVpuLWV1eDBoeUxWVDI3ZW04OHV0SjVnWWE4ZS1OX0ZoaW5jX0pPZHFnbXhkcGctb24tNjdlMlhoa3ZnMmZ5UjJDUm1wNEd6a1hpa1F2cHhOVS1zZDU0WmJ1NEdyMVlMdHZtZnVIUldnZWdvUQ?oc=5", "source_name": "BioSpace", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas inks license agreement with InnoCare for 3 autoimmune programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQLWlsaHN1clBVTFUxNXRPZDhYckUtQUpyYlJuYVV4TVNNOHhNRFFHRGFZalB1blQwSkdLVVd1OVpkVmh5bkhlYTFBMkRCZHFxTEhsWndTQzRjbko3dkhCUkd6WFdRc0JMTVA5YVEzV1dJWEd5VW9QZ1RFUm4zZThlSHVFcENKZjM3a0djVUJObDc1cVNia0lOOWZFTnUzQVNDbWVHX2owZ0hQTEpPeHpsS2Vsdw?oc=5", "source_name": "The Pharma Letter", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InnoCare, Keymed sell ex-China rights for bispecific to RTW-built biotech in $520M deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNUzY5emJTMlJWWll5Nmo5VmtBX0ZCRUFZNk9FSXRPdFhjUTRxV1VGYTZ1ZW9lajlMUUdJNGxJUTgzeldaeXZhUVdRZG9mam1CRVRudW5wQkx2bTFXUWhFMll6bm4xd3ZkUHF1aWExQjRLcF9Na1RXd29falVsWTFweWhzdzk4Sk1hUk1VaDhZakhVczhZdHRYSHVZSW83dVB5OG9VdE8td0J5VmU1UFY2UHdKMA?oc=5", "source_name": "Fierce Biotech", "published_at": "2025-01-21T08:00:00+00:00", "published_display": "21 Jan 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of InnoCare Pharma Ltd. Class A (SSE:688428)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE1UTWh5OUM2T0poNVVaT043elVKT1FOYm9xNFpady1NVHZYX19PRGtTOEdvdF8tMGN0TnNicGpCX05FMFFUZ1RPWUVmNHZ6SURIZ3hlQzh0elEzbmt2a1hYUWpudlp3WjZ4Znc?oc=5", "source_name": "TradingView", "published_at": "2023-03-30T11:22:07+00:00", "published_display": "30 Mar 2023 11:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "InnoCare Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE9NdVBtOFJlNkN3UWE0OWtFdjlVWGl6TW9fRHROZGRvVVlFWXVmSzc2ZS1uejZ5ZFJFOFN4NWpVd2N3cXltTkZJb1MtdEs4bXdLaWQ4QklUWHB3a1poTmdkTHhvLUFYaHFFTG5qNGJB?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-07-20T19:38:49+00:00", "published_display": "20 Jul 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-14T10:21:47+00:00", "published_display": "14 Jul 2026 10:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is InnoCare Pharma (SEHK:9969) Undervalued On Its Breakthrough Lupus Trial Results?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T22:20:48+00:00", "published_display": "10 Jul 2026 22:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOTFZOcGNETTBDSVRLS3BwS0NiandvMVluTjd6eW91S1g2MW1OMW5pWXZCYUt2TldxeFlUaEFJaGpBZjY2YjRCd0dQQm4yTUNjOXI0M3dDSU1ZNEVHQzhUYWxmOXlEWWE0TlVnSVJzNGprbHlDR1lkanZVckNJbEtkNkVhT3lyaGJ6WWxjMWkwa2VYN3N3eTJhMDRwemZmMU1KZ3RTWnpLdjlVeEtIdGNEVkJWRlZ2aENwNjhEX29DaFl5RkFYNkpCWA?oc=5", "source_name": "Sahm", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InnoCare Pharma posts 134% revenue surge in 2025, recording annual profit for first time", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBiTWtVUlBZeHRyNE9Kc0dSVEJFWjBweFo3X2ZLZHB4V19JMk5tcUhISWhzbWVPdDJrenNnWGhqdm5jZUxhZlVjdGQxem12M3kyZ0syTml5anVwR0R2bkFUSi1EczVVMDJvNUNfdDVGakFRcnJjQUF4WFNIS0pBQQ?oc=5", "source_name": "China Daily", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas makes big bet on MS drug, striking $2B licensing deal with InnoCare", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOU1VfUnJXTE5fTUNGa1VoMk1oQzlWT28zRzdVUTkzaVJDYS1qbjh6VGlGSDZVRUdBWHRQakRqbUYxNmtCdTZ5N1VJOG5scVhnVWFRUThlS01yV3UxT3hZaHhwLUFIb1RaeTUyX0NuUXJPSURmS09OeGY1ck8tUF84T1JnS2NRMnoyYkFzbVNacGo3QzUtUHUweUEwVDR3Rm04?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcHRlT1lSSWxFZVFQWFhFRlFqcnFteFBiSnJjc3ZLMl9XUWRFcERwNVZheDNFZnJUTzNGWnVnSlJmYVJaUWpNTi1OX2EtTElkT2ZVYzhDSEJpRmVFdmMySmlaU1lrZ296V1RqUVhYZlpxWW5SUUtaT0pubENwbUZVV2JtYWY0aEhnUGpSMmE5UXh6Sl9FY3BDQy1jVUJyeWJzYW40akdRMVJCOGxuRHM3QUE0N0ZrVHUyMlhuOTNfdUhzQmVURUR6d2JuVTluemxpRkxaSmxudjFjdw?oc=5", "source_name": "Reuters", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPeHlXLWxLOU8wS1hRTUNtU3lFR0x6c3RXWXZpYVItWHNGd1FqLW92MVpuLWV1eDBoeUxWVDI3ZW04OHV0SjVnWWE4ZS1OX0ZoaW5jX0pPZHFnbXhkcGctb24tNjdlMlhoa3ZnMmZ5UjJDUm1wNEd6a1hpa1F2cHhOVS1zZDU0WmJ1NEdyMVlMdHZtZnVIUldnZWdvUQ?oc=5", "source_name": "BioSpace", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas inks license agreement with InnoCare for 3 autoimmune programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQLWlsaHN1clBVTFUxNXRPZDhYckUtQUpyYlJuYVV4TVNNOHhNRFFHRGFZalB1blQwSkdLVVd1OVpkVmh5bkhlYTFBMkRCZHFxTEhsWndTQzRjbko3dkhCUkd6WFdRc0JMTVA5YVEzV1dJWEd5VW9QZ1RFUm4zZThlSHVFcENKZjM3a0djVUJObDc1cVNia0lOOWZFTnUzQVNDbWVHX2owZ0hQTEpPeHpsS2Vsdw?oc=5", "source_name": "The Pharma Letter", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "InnoCare, Keymed sell ex-China rights for bispecific to RTW-built biotech in $520M deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNUzY5emJTMlJWWll5Nmo5VmtBX0ZCRUFZNk9FSXRPdFhjUTRxV1VGYTZ1ZW9lajlMUUdJNGxJUTgzeldaeXZhUVdRZG9mam1CRVRudW5wQkx2bTFXUWhFMll6bm4xd3ZkUHF1aWExQjRLcF9Na1RXd29falVsWTFweWhzdzk4Sk1hUk1VaDhZakhVczhZdHRYSHVZSW83dVB5OG9VdE8td0J5VmU1UFY2UHdKMA?oc=5", "source_name": "Fierce Biotech", "published_at": "2025-01-21T08:00:00+00:00", "published_display": "21 Jan 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of InnoCare Pharma Ltd. Class A (SSE:688428)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE1UTWh5OUM2T0poNVVaT043elVKT1FOYm9xNFpady1NVHZYX19PRGtTOEdvdF8tMGN0TnNicGpCX05FMFFUZ1RPWUVmNHZ6SURIZ3hlQzh0elEzbmt2a1hYUWpudlp3WjZ4Znc?oc=5", "source_name": "TradingView", "published_at": "2023-03-30T11:22:07+00:00", "published_display": "30 Mar 2023 11:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 68, "total_relevant": 11, "sentiment_summary": {"positive": 2, "negative": 1, "neutral": 8, "score": 54, "total": 11, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 2.0, "count": 3}, {"event": "earnings", "label": "Earnings", "weight": 1.65, "count": 3}], "positive_events": 2, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 26.52, "latest_week": "2026-07-17", "one_week_move": -10.9, "four_week_move": 11.1, "twelve_week_move": -6.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.223652, "market_dynamics_buy_signal": false, "relative_strength": 7.828613, "fair_value_gap": 55.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.194, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.9% over one week, +11.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "The Pharma Letter", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Sahm", "count": 1}, {"label": "China Daily", "count": 1}, {"label": "Fierce Pharma", "count": 1}, {"label": "Reuters", "count": 1}, {"label": "BioSpace", "count": 1}, {"label": "Fierce Biotech", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 11}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 5}, {"label": "Earnings", "count": 3}, {"label": "Deals and strategy", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "11", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-10.9% over one week, +11.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "InnoCare Pharma"}], "updated_at": "2026-07-21T23:02:57.112687+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}